KR20230090184A - Pharmaceutical composite formulation comprising esomeprazole and rebamipide - Google Patents

Pharmaceutical composite formulation comprising esomeprazole and rebamipide Download PDF

Info

Publication number
KR20230090184A
KR20230090184A KR1020210179212A KR20210179212A KR20230090184A KR 20230090184 A KR20230090184 A KR 20230090184A KR 1020210179212 A KR1020210179212 A KR 1020210179212A KR 20210179212 A KR20210179212 A KR 20210179212A KR 20230090184 A KR20230090184 A KR 20230090184A
Authority
KR
South Korea
Prior art keywords
quadruple
tablet
rebamipide
zollinger
gerd
Prior art date
Application number
KR1020210179212A
Other languages
Korean (ko)
Inventor
나도현
강경표
전진환
Original Assignee
메디케어제약 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메디케어제약 주식회사 filed Critical 메디케어제약 주식회사
Priority to KR1020210179212A priority Critical patent/KR20230090184A/en
Publication of KR20230090184A publication Critical patent/KR20230090184A/en

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to a pharmaceutical composite formulation which contains esomeprazole and rebamipide to treat gastric ulcers and gastric mucosal lesions (erosions, bleeding, redness, and edema) accompanied by gastroesophageal reflux disease (GERD) and Zollinger-Ellison syndrome. In the present invention, when treating gastric ulcers and gastric mucosal lesions (erosions, bleeding, redness, edema) accompanied by GERD and Zollinger-Ellison syndrome, it is possible to not only solve the problem of not only having to take each individual ingredient individually, but also the inconvenience of having to take it multiple times due to the short duration of the treatment effect, and the burden of economic costs due to rising drug prices.

Description

에스오메프라졸 및 레바미피드를 포함하는 약제학적 복합제제 {Pharmaceutical composite formulation comprising esomeprazole and rebamipide}Pharmaceutical composite formulation comprising esomeprazole and rebamipide

본 발명은 위식도 역류질환(GERD) 및 졸링거-엘리슨 증후군을 동반한 위궤양 및 위점막병변(미란,출혈,발적,부종)을 치료하는 에스오메프라졸(esomeprazole) 및 레바미피드(rebamipide) 성분을 포함하는 약제학적 복합제제에 관한 것이다.The present invention provides esomeprazole and rebamipide components for treating gastric ulcers and gastric mucosal lesions (erosion, bleeding, redness, edema) associated with gastroesophageal reflux disease (GERD) and Zollinger-Ellison syndrome. It relates to a pharmaceutical combination preparation comprising

일반적으로 위식도 역류질환(GERD) 및 졸링거-엘리슨 증후군은 에스오메프라졸(esomeprazole) 단독 성분의 제제로 치료하고, In general, gastroesophageal reflux disease (GERD) and Zollinger-Ellison syndrome are treated with esomeprazole alone.

위궤양 및 위점막병변(미란,출혈,발적,부종)의 치료는 레바미피드(rebamipide) 단독 성분의 제제로 치료한다.Treatment of gastric ulcer and gastric mucosal lesions (erosion, bleeding, redness, edema) is treated with preparations containing only rebamipide.

위식도 역류질환(GERD) 및 졸링거-엘리슨 증후군을 치료하기 위해 에스오메프라졸(esomeprazole) 단독 성분의 제제는 1일 2회 정도 복용하고,To treat gastroesophageal reflux disease (GERD) and Zollinger-Ellison syndrome, esomeprazole alone is taken twice a day,

위궤양 및 위점막병변(미란,출혈,발적,부종)을 치료하기 위해 레바미피드(rebamipide) 단독 성분의 제제는 1일 3회 정도 복용한다.In order to treat gastric ulcer and gastric mucosal lesions (erosion, bleeding, redness, edema), rebamipide-only preparations are taken three times a day.

대한민국 특허 공개 제1020050050145호Korean Patent Publication No. 1020050050145 대한민국 특허 공개 제1020100051850호Korean Patent Publication No. 1020100051850

본 발명은 위식도 역류질환(GERD) 및 졸링거-엘리슨 증후군을 동반한 위궤양 및 위점막병변(미란,출혈,발적,부종)을 치료하는 경우,The present invention treats gastric ulcers and gastric mucosal lesions (erosion, bleeding, redness, edema) accompanied by gastroesophageal reflux disease (GERD) and Zollinger-Ellison syndrome,

각 단독 성분의 제제를 개별적으로 복용해야 할 뿐만 아니라 치료 효과 지속 시간이 짧아 여러 번 복용해야 하는 번거로움과 약가 상승에 따른 경제적 비용 부담이 발생하는 문제점을 해결한다.It solves the problem of not only having to take each individual ingredient separately, but also the inconvenience of having to take multiple doses due to the short duration of treatment effect and the burden of economic costs due to rising drug prices.

본 발명은 1개의 치료제로 사중정을 복합 구성하고 있는 4종의 제제 중에서 위식도 역류질환(GERD) 및 졸링거-엘리슨 증후군을 일차로 치료하기 위해 에스오메프라졸(esomeprazole) 속효성 제제(immediately release)를 포함하는 사중정,The present invention provides an immediate release of esomeprazole to treat gastroesophageal reflux disease (GERD) and Zollinger-Ellison syndrome as a primary treatment among four formulations comprising a quadruple tablet as one therapeutic agent. containing quartet,

1개의 치료제로 사중정을 복합 구성하고 있는 4종의 제제 중에서 위식도 역류질환(GERD) 및 졸링거-엘리슨 증후군을 이차로 치료하기 위해 에스오메프라졸(esomeprazole) 서방형 제제(extended release)를 포함하는 사중정,Among the 4 types of formulations that consist of a quadruple tablet as one therapeutic agent, esomeprazole extended release formulations are included for the secondary treatment of gastroesophageal reflux disease (GERD) and Zollinger-Ellison syndrome. quartet,

1개의 치료제로 사중정을 복합 구성하고 있는 4종의 제제 중에서 위궤양 및 위점막병변(미란,출혈,발적,부종)을 일차로 치료하기 위해 레바미피드(rebamipide) 속효성 제제(immediately release)를 포함하는 사중정,Among the 4 types of formulations that make up the quadruple tablet as one treatment, rebamipide (immediately release) is included for the primary treatment of gastric ulcer and gastric mucosal lesions (erosion, bleeding, redness, edema). quartet to do,

1개의 치료제로 사중정을 복합 구성하고 있는 4종의 제제 중에서 위궤양 및 위점막병변(미란,출혈,발적,부종)을 이차로 치료하기 위해 레바미피드(rebamipide) 서방형 제제(extended release)를 포함하는 사중정으로 구성된다.Among the 4 types of formulations that consist of a quadruple tablet as one treatment, rebamipide (extended release) is selected for the secondary treatment of gastric ulcer and gastric mucosal lesions (erosion, bleeding, redness, edema). It consists of a quartet containing

본 발명은 위식도 역류질환(GERD) 및 졸링거-엘리슨 증후군을 동반한 위궤양 및 위점막병변(미란,출혈,발적,부종)을 4종의 제제로 복합 구성된 1개의 사중정으로 치료함으로써, The present invention treats gastric ulcers and gastric mucosal lesions (erosion, bleeding, redness, edema) accompanied by gastroesophageal reflux disease (GERD) and Zollinger-Ellison syndrome with one quadruple tablet composed of four types of agents,

위식도 역류질환(GERD) 및 졸링거-엘리슨 증후군 그리고 위궤양 및 위점막병변(미란,출혈,발적,부종)의 치료 효과 지속 시간이 길어지도록 하여 복용의 편의성과 경제적 효율성이 개선된 새로운 약제학적 복합제제 제공의 효과를 가진다.A new pharmaceutical complex with improved convenience and economic efficiency by prolonging the duration of treatment effects for gastroesophageal reflux disease (GERD), Zollinger-Ellison syndrome, gastric ulcer and gastric mucosal lesions (erosion, bleeding, redness, edema) It has the effect of providing an agent.

도 1 : 본 발명의 상세도Figure 1 : Detailed view of the present invention

본 발명은 1개의 치료제로 사중정을 복합 구성하고 있는 4종의 제제 중에서 위식도 역류질환(GERD) 및 졸링거-엘리슨 증후군을 일차로 치료하기 위해 에스오메프라졸(esomeprazole) 속효성 제제(immediately release)를 포함하는 사중정(100),The present invention provides an immediate release of esomeprazole to treat gastroesophageal reflux disease (GERD) and Zollinger-Ellison syndrome as a primary treatment among four formulations comprising a quadruple tablet as one therapeutic agent. A quartet containing (100),

1개의 치료제로 사중정을 복합 구성하고 있는 4종의 제제 중에서 위식도 역류질환(GERD) 및 졸링거-엘리슨 증후군을 이차로 치료하기 위해 에스오메프라졸(esomeprazole) 서방형 제제(extended release)를 포함하는 사중정(200),Among the 4 types of formulations that consist of a quadruple tablet as one therapeutic agent, esomeprazole extended release formulations are included for the secondary treatment of gastroesophageal reflux disease (GERD) and Zollinger-Ellison syndrome. Quadruple Court (200),

1개의 치료제로 사중정을 복합 구성하고 있는 4종의 제제 중에서 위궤양 및 위점막병변(미란,출혈,발적,부종)을 일차로 치료하기 위해 레바미피드(rebamipide) 속효성 제제(immediately release)를 포함하는 사중정(300),Among the 4 types of formulations that make up the quadruple tablet as one treatment, rebamipide (immediately release) is included for the primary treatment of gastric ulcer and gastric mucosal lesions (erosion, bleeding, redness, edema). quadruple (300) to do,

1개의 치료제로 사중정을 복합 구성하고 있는 4종의 제제 중에서 위궤양 및 위점막병변(미란,출혈,발적,부종)을 이차로 치료하기 위해 레바미피드(rebamipide) 서방형 제제(extended release)를 포함하는 사중정(400)으로 구성된다.Among the 4 types of formulations that consist of a quadruple tablet as one treatment, rebamipide (extended release) is selected for the secondary treatment of gastric ulcer and gastric mucosal lesions (erosion, bleeding, redness, edema). It consists of a quartet (400) containing

100. 에스오메프라졸(esomeprazole) 속효성 제제(immediately release)를 포함하는 사중정(100),
200. 에스오메프라졸(esomeprazole) 서방형 제제(extended release)를 포함하는 사중정(200),
300. 레바미피드(rebamipide) 속효성 제제(immediately release)를 포함하는 사중정(300),
400. 레바미피드(rebamipide) 서방형 제제(extended release)를 포함하는 사중정(400)100. Quadruple tablet (100) containing esomeprazole immediate release,
200. Quadruple tablet (200) containing esomeprazole extended release,
300. Quadruple tablet 300 containing rebamipide immediate release,
400. Quadruple tablet (400) containing rebamipide extended release

Claims (1)

1개의 치료제로 사중정을 복합 구성하고 있는 4종의 제제 중에서 위식도 역류질환(GERD) 및 졸링거-엘리슨 증후군을 일차로 치료하기 위해 에스오메프라졸(esomeprazole) 속효성 제제(immediately release)를 포함하는 사중정, 1개의 치료제로 사중정을 복합 구성하고 있는 4종의 제제 중에서 위식도 역류질환(GERD) 및 졸링거-엘리슨 증후군을 이차로 치료하기 위해 에스오메프라졸(esomeprazole) 서방형 제제(extended release)를 포함하는 사중정, 1개의 치료제로 사중정을 복합 구성하고 있는 4종의 제제 중에서 위궤양 및 위점막병변(미란,출혈,발적,부종)을 일차로 치료하기 위해 레바미피드(rebamipide) 속효성 제제(immediately release)를 포함하는 사중정, 1개의 치료제로 사중정을 복합 구성하고 있는 4종의 제제 중에서 위궤양 및 위점막병변(미란,출혈,발적,부종)을 이차로 치료하기 위해 레바미피드(rebamipide) 서방형 제제(extended release)를 포함하는 사중정으로 구성되어, 위식도 역류질환(GERD) 및 졸링거-엘리슨 증후군을 동반한 위궤양 및 위점막병변(미란,출혈,발적,부종)을 치료하는 에스오메프라졸(esomeprazole) 및 레바미피드(rebamipide) 성분을 포함하는 약제학적 복합제제Among the 4 types of formulations comprising a quadruple tablet as one therapeutic agent, a drug containing esomeprazole immediate release for the primary treatment of gastroesophageal reflux disease (GERD) and Zollinger-Ellison syndrome Among the 4 types of formulations that consist of a quadruple tablet as a quadruple tablet, esomeprazole extended release is selected for the secondary treatment of gastroesophageal reflux disease (GERD) and Zollinger-Ellison syndrome. Among the four types of formulations that consist of a quadruple tablet with one treatment and a quadruple tablet with one treatment, rebamipide is a fast-acting agent ( Among the four types of formulations consisting of a quadruple tablet with immediate release) and a quadruple tablet as one treatment, rebamipide is used for secondary treatment of gastric ulcer and gastric mucosal lesions (erosion, bleeding, redness, and edema). ) Consists of a quadruple tablet containing extended release, which treats gastric ulcers and gastric mucosal lesions (erosion, bleeding, redness, and swelling) accompanied by gastroesophageal reflux disease (GERD) and Zollinger-Ellison syndrome. Pharmaceutical combination preparation containing esomeprazole and rebamipide components
KR1020210179212A 2021-12-14 2021-12-14 Pharmaceutical composite formulation comprising esomeprazole and rebamipide KR20230090184A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020210179212A KR20230090184A (en) 2021-12-14 2021-12-14 Pharmaceutical composite formulation comprising esomeprazole and rebamipide

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020210179212A KR20230090184A (en) 2021-12-14 2021-12-14 Pharmaceutical composite formulation comprising esomeprazole and rebamipide

Publications (1)

Publication Number Publication Date
KR20230090184A true KR20230090184A (en) 2023-06-21

Family

ID=86989941

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020210179212A KR20230090184A (en) 2021-12-14 2021-12-14 Pharmaceutical composite formulation comprising esomeprazole and rebamipide

Country Status (1)

Country Link
KR (1) KR20230090184A (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050050145A (en) 2002-10-18 2005-05-27 아스트라제네카 아베 Method for the synthesis of a benzimidazole compound
KR20100051850A (en) 2007-08-10 2010-05-18 오츠카 세이야쿠 가부시키가이샤 Medical composition containing rebamipide

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050050145A (en) 2002-10-18 2005-05-27 아스트라제네카 아베 Method for the synthesis of a benzimidazole compound
KR20100051850A (en) 2007-08-10 2010-05-18 오츠카 세이야쿠 가부시키가이샤 Medical composition containing rebamipide

Similar Documents

Publication Publication Date Title
AR107871A1 (en) COMBINATIONS OF LSD1 INHIBITORS FOR USE IN THE TREATMENT OF SOLID TUMORS
TW200744636A (en) Combined treatment with and composition of 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitor and anti-cancer agents
RU2011104570A (en) COMBINATION (A) OF PHOSPHOINOZIT-3-KINASE INHIBITOR AND (B) PATH MODULATOR Ras / Raf / Mek
NO20013859D0 (en) Cyclooxygenase-2 inhibitor preparations that rapidly provide therapeutic effect
GT200600096A (en) PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT
UA90858C2 (en) Controlled-release formulations containing vardenafil
DK1317419T3 (en) Cyanophenoxycarboxylic acid compounds and compositions to deliver active agents
RS52922B (en) Compositions and uses for treating multiple sclerosis
EA201590166A8 (en) COMBINED THERAPY FOR THE TREATMENT OF SCATTERED SCLEROSIS
CR8603A (en) HYDROCLORIDE OF [4- (5-AMINOMETIL-2-FLUORO-PHENYL) -PIPERIDIN-1-IL] - (4-BROMO-3-METHYL-5-PROPOXI-THIOFEN-2-IL) -METANONE AS AN INHIBITOR OF THE MASTOCYT TRIPTASE
EP2578214A4 (en) Pharmaceutical composition for the prevention or treatment of inflammatory diseases or immune diseases containing ramalin
RU2014129508A (en) NEW COMBINATION
EP4241855A3 (en) Antibacterial activity of galactooligosaccharide and xylitol in dermatological treatments
CL2021003032A1 (en) Methods of treating chronic spontaneous urticaria using a Bruton's tyrosine kinase inhibitor.
NZ598031A (en) Inhibition of the tumorigenic potential of tumor stem cells by lif and bmps
HUP0302913A2 (en) Methods of inducing cancer cell death and tumor regression and preparation of pharmaceutical compositions suitable for treating the same
Buckley et al. Multiple keratoses and squamous carcinoma after PUVA treatment of vitiligo
ES2124983T3 (en) USE OF A SUBSTANCE P ANTAGONIST FOR THE TREATMENT OF RED SKIN STAINS OF NEUROGENOUS ORIGIN.
AR033390A1 (en) A PHARMACEUTICAL COMPOSITION THAT INCLUDES AN ATTA RECEIVER ANTAGONIST AND A POTENTIATOR OF THE INSULIN SECRETION, THE USE OF SUCH COMPOSITION FOR THE MANUFACTURE OF A MEDICINAL PRODUCT AND A PARTS KIT
KR20230090184A (en) Pharmaceutical composite formulation comprising esomeprazole and rebamipide
EA201891235A1 (en) COMPOSITIONS OF MEDICINES FOR THE TREATMENT OF MALIGNANT TUMOR
MX2023000870A (en) Diester cosmetic formulations and uses thereof.
PA8525801A1 (en) PIRAZOL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS TO MODULATE AND / OR INHIBIT THE ACTIVITY OF ERAB / HADH2
WO2006117404A3 (en) Topical use of radical capturing substances for antipyretic treatment
ATE283059T1 (en) USE OF A COMPOUND CONTAINING POLLEN EXTRACT TO TREAT IRRITABILITY